Stifel Nicolaus Issues Pessimistic Forecast for Astrana Health (NASDAQ:ASTH) Stock Price

Astrana Health (NASDAQ:ASTH) had its price target dropped by investment analysts at Stifel Nicolaus from $70.00 to $56.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 56.95% from the company’s previous close.

ASTH has been the topic of a number of other reports. Truist Financial decreased their target price on Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, January 13th. Macquarie upgraded shares of Astrana Health to a “hold” rating in a research report on Monday, December 16th. Finally, Robert W. Baird lifted their target price on shares of Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $63.00.

Astrana Health Trading Down 4.6 %

Astrana Health stock opened at $35.68 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. Astrana Health has a fifty-two week low of $29.08 and a fifty-two week high of $63.20. The stock has a market cap of $2.01 billion, a P/E ratio of 27.45, a PEG ratio of 1.51 and a beta of 1.20. The firm’s fifty day moving average price is $35.06 and its 200-day moving average price is $44.99.

Institutional Trading of Astrana Health

Several hedge funds and other institutional investors have recently bought and sold shares of ASTH. PharVision Advisers LLC purchased a new position in shares of Astrana Health during the fourth quarter worth approximately $211,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Astrana Health by 15.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,658 shares of the company’s stock valued at $3,300,000 after purchasing an additional 14,138 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Astrana Health in the 4th quarter worth $1,208,000. Two Sigma Investments LP bought a new stake in Astrana Health in the fourth quarter worth $466,000. Finally, Sherbrooke Park Advisers LLC purchased a new stake in Astrana Health during the fourth quarter valued at about $494,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.